This article is being retracted from Bioscience Reports at the request of the Editor-in-Chief and the Editorial Board following receipt of a notification from a reader, alerting the Editorial Board to concerns surrounding the appearance of Western blots in this paper, and an image in this paper that seems to appear in another article. The Western blots appear to have minimal background details and share similarities with other Western blots present in papers by different authors. Additionally, Figure 2D U87 miR-NC panel seems to appear as Figure 2E H1299 miR-33b inhibitor panel from Zhai et al, 2019 (DOI: 10.1002/jcb.27961) with rotation. The authors have been contacted with regards to the retraction and have not responded to the Journal's queries or the concerns raised. Given the extent of the issues raised, the Editorial Board stand by the decision to retract the article.
Skip Nav Destination
Article navigation
July 2024
-
Cover Image
Cover Image
This month's cover of Bioscience Reports features a cartoon depicting two orthogonal views of the three-dimensional structure of a designed His6-TAT peptide (left) and the BoNT/B-LC active site (right), read more in ‘Expression, purification and application of a recombinant, membrane permeating version of the light chain of botulinum toxin B’ by Tomes and colleagues.
Retraction|
July 03 2024
Retraction: MiR-205 suppresses epithelial-mesenchymal transition and inhibits tumor growth of human glioma through downregulation of HOXD9
Publisher: Portland Press Ltd
Online ISSN: 1573-4935
Print ISSN: 0144-8463
© 2024 The Author(s).
2024
This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Biosci Rep (2024) 44 (7): BSR-2018-1989_RET.
Citation
Retraction: MiR-205 suppresses epithelial-mesenchymal transition and inhibits tumor growth of human glioma through downregulation of HOXD9. Biosci Rep 31 July 2024; 44 (7): BSR–2018–1989_RET. doi: https://doi.org/10.1042/BSR-2018-1989_RET
Download citation file:
477
Views
Cited By
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |